Lilly's insulin shows superiority over Lantus but drug safety a concern
This article was originally published in Scrip
Executive Summary
Lilly's basal insulin product peglispro (LY2605541) significantly lowered HbA1c levels in type 1 diabetes patients in Phase III trials compared with Sanofi's market-leading treatment Lantus (insulin glargine), but safety questions remain